Some more promotion of Cellmid's pipeline. Details of the Biotecnol deal have appeared in the Proactive Investors current newsletter.
http://www.proactiveinvestors.com.au/companies/news/54356/cellmid-signs-agreement-with-biotecnol-into-immuno-oncology-sector-54356.html
The article's concluding analysis states:
"Biotecnol's strong track record in antibody drug development is significant.
With these novel drugs the subject of significant deals worth US$5 billion in acquisition and license fees of mostly pre-clinical stage compounds since 2009, provides a potential new area of growth for Cellmid.
Given that Cellmid’s existing midkine antibodies are expected to become clinic-ready by the end of 2014, there is considerable growth ahead for the company.
We continue to estimate a share price target of $0.041 to $0.068 for Cellmid within the next 12 months on its rising cash flows and progress towards clinical trials."
T7
- Forums
- ASX - By Stock
- pipeline update
Some more promotion of Cellmid's pipeline. Details of the...
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AN1 (ASX) to my watchlist
|
|||||
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 565639 | 0.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.9¢ | 80000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 565639 | 0.006 |
1 | 300000 | 0.005 |
2 | 525000 | 0.004 |
1 | 600000 | 0.003 |
2 | 500000 | 0.002 |
Price($) | Vol. | No. |
---|---|---|
0.009 | 80000 | 1 |
0.010 | 157763 | 1 |
0.015 | 340000 | 2 |
0.016 | 100000 | 1 |
0.017 | 110000 | 1 |
Last trade - 16.12pm 03/09/2024 (20 minute delay) ? |
Featured News
AN1 (ASX) Chart |
Day chart unavailable